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Objective: To determine the prevalence of the metabolic syndrome (MetS) and its components in Brazilian women
with polycystic ovary syndrome (PCOS).
Design: Cross-sectional study.
Setting: University Hospital, Federal University of Rio Grande do Norte, Natal-RN, Brazil.
Patient(s): 102 women with PCOS by the Rotterdam consensus criteria.
Intervention(s): None.
Main Outcome Measure(s): Clinical and biochemical parameters for MetS as defined by the National Cholesterol
Education Program Adult Treatment Panel (NCEP ATP III).
Result(s): The prevalence for individual components of MetS were high-density lipoprotein cholesterol level<50
mg/dL in 69.6%, waist circumferenceR88 cm in 57.9%, triglyceride levelR150 mg/dL in 31.7%, blood pressure
R130/85 mm Hg in 18.6%, and fasting glucose concentrations R110 mg/dL in 2.9%. Three or more of these
individual criteria were present in 29 (28.4%) of the patients. The prevalence of MetS increased with body
mass index: 3.2%, 19.2% and 52.3% for normal, overweight, and obese women, respectively.
Conclusion(s): These findings indicate that Brazilian women with PCOS have a high prevalence of MetS and its
individual components, particularly a decreased high-density lipoprotein cholesterol level. Thus, these women are
at increased risk of diabetes mellitus and cardiovascular disease. (Fertil Steril 2008;89:649–55.2008 by Amer-
ican Society for Reproductive Medicine.)
Key Words: Metabolic syndrome, polycystic ovary syndrome, cardiovascular diseasePolycystic ovary syndrome (PCOS) is one of the most com-
mon endocrine diseases in women, affecting approximately
5% to 8% of premenopausal women (1–3). This ovarian dis-
function syndrome is characterized by chronic anovulation,
oligomenorrhea or amenorrhea, hyperandrogenism, infertil-
ity, and polycystic ovary morphology (4). Additionally, it is
recognized to have a metabolic component consisting of hy-
perinsulinemic insulin resistance; this finding has led to the
correlation of PCOS with increased cardiovascular disease
risk, which occurs in both lean and obese women with the
disorder (5, 6).
Themetabolic syndrome (MetS) is another cluster of endo-
crine disturbances, including insulin resistance, dyslipide-
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has been associated with a twofold increased risk of cardio-
vascular disease and a fivefold increased risk of type 2 diabe-
tes (9). Estimates of the prevalence of MetS in women with
PCOS have been based mainly on the U.S. population, point-
ing to a prevalence of approximately 43% to 46% (10–12).
Despite this increased prevalence, the exact relationship
between insulin resistance and different features of MetS
in PCOS patients is not completely understood.
There are few data concerning this prevalence in other
countries, especially in those where obesity is less frequently
found than in the United States. Studies involving Czech and
Italian women with PCOS report that MetS and its compo-
nents were much less frequent in these populations (13,
14), a finding attributed to genetic factors and differences
in lifestyle and dietary habits, and, possibly also influenced
by the criteria used to diagnose MetS, as well as the criteria
used to diagnose PCOS.
In the Brazilian population, the prevalence of obesity, in-
creased waist circumference, hypertension, and dyslipidemia
is markedly less than observed in the United States (15).
Within this context, no data are published on the prevalenceFertility and Sterility Vol. 89, No. 3, March 2008 649
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of MetS and its components in Brazilian women with PCOS.
Our purpose was to estimate this prevalence according to the
National Cholesterol Education Program Adult Treatment
Panel III (ATP-III) criteria (16).
MATERIALS AND METHODS
Patients
Clinical, anthropometric, biochemical, and hormonal mea-
sures were taken of 102 women with PCOS who participated
in a cross-sectional study designed to evaluate the association
between PCOS and cardiovascular disease. Volunteers were
selected at the University Hospital of the Federal University
of Rio Grande do Norte, Natal-RN, Brazil, from July 2004 to
December 2005. This study was approved by the institutional
ethics committee (protocol number 126/04), and all volun-
teers gave written informed consent.
Women aged 20 to 34 years who wereR2 years postme-
narchewere eligible for the study. No classification according
to ethnicity was used, as it is very difficult to classify ethnic
groups in Brazil where there is abundant racial admixture; the
autoreference according to race or color may be not adequate,
with significant dissociation of color and genomic ancestry
(17, 18).
The diagnosis of PCOS was made according to the criteria
of the Rotterdam ESHRE-ASRM–sponsored PCOS consen-
sus workshop (4) by the presence of at least two of the follow-
ing three features: [1] oligo-ovulation and/or anovulation,
characterized by oligomenorrhea (intermenstrual intervals
of 45 days or more or fewer than eight menses per year), or
amenorrhea (intervals >3 months); [2] clinical signs of an-
drogen excess (Ferriman–Gallwey [19] hirsutism score R8
and/or presence of acne), and/or biochemical signs of hyper-
androgenism; and [3] ultrasonographic findings of ovarian
polycystic morphology (presence of R12 follicles in each
ovary measuring 2 to 9 mm in diameter, and/or increased
ovarian volume >10 mL) (4).
Infertility was defined as the inability to conceive after 1
year of unprotected intercourse. The exclusion of other disor-
ders such as nonclassic congenital adrenal hyperplasia,
thyroid dysfunction, and hyperprolactinemia was also con-
sidered. Other exclusion criteria for this study were renal or
hepatic dysfunction or use of medications known to affect re-
productive or metabolic function, such as oral contraceptives,
antiandrogen drugs, antidiabetic treatment, statins, or gluco-
corticoid therapy within 60 days of study entry. Both Rotter-
dam-PCOS criteria and Ferriman–Gallwey score were
assessed by at least two observers.
Althoughmany diagnostic criteria forMetS have been pro-
posed, the National Cholesterol Education Program Adult
Treatment Panel III (ATP-III) criteria are the most commonly
used for both clinical and research purposes, so these criteria
were adopted for our study as well (16). Thus, the MetS was
defined by the presence of three or more of the following ab-
normalities: waist circumferenceR88 cm; fasting serum glu-650 Soares et al. Metabolic syndrome in Brazilian PCOScose of at least 110 mg/dL; fasting serum triglyceridesR150
mg/dL; serum high-density lipoprotein cholesterol (HDL-C)
<50 mg/dL; and blood pressureR130/85 mm Hg.
Study Protocol
All patients underwent a clinical examination where body
weight, height, waist and hip circumferences and blood pres-
sure were measured. Body mass index (BMI) was calculated
as weight in kilograms divided by the square of height in me-
ters (kg/m2); overweight was defined as a BMI between 25.0
and 29.9, and obese as 30.0 or higher, according to World
Health Organization categories (20). Acanthosis nigricans,
a significant marker for insulin resistance (21), was diag-
nosed by hyperpigmentation of the skin in the posterior re-
gion of the neck, axillae, antecubital fossae, and groin.
Fasting venous blood samples were collected between 8:00
AM and 10:00 AM after a 12-hour overnight fast. Serum glu-
cose was measured by the glucose oxidase method. Levels
of total cholesterol, high-density lipoprotein cholesterol
(HDL-C), triglycerides, aspartate aminotransferase (AST),
alanine aminotransferase (ALT), gamma-glutamyltransfer-
ase (GGT), urea, and creatinine were determined by enzy-
matic colorimetric assays (BioSystems, Barcelona, Spain).
Low-density lipoprotein (LDL) levels were calculated by
using Friedewald’s formula.
Blood samples also were obtained at baseline and at 30-
minute intervals for 2 hours during a 75-g oral glucose toler-
ance test (OGTT) to measure glucose and insulin. Glucose
tolerance was evaluated using the American Diabetes Associ-
ation’s criteria for the diagnosis and classification of diabetes
(22). Insulin sensitivity was evaluated by the quantitative
insulin-sensitivity check index (QUICKI): 1/(log insulin
[mU/mL] þ log glucose [mg/dL]) (23).
Levels of follicle-stimulating hormone (FSH), luteinizing
hormone (LH), and insulin were determined by using
commercially available diagnostic kits in the IMMULITE
2000 automated chemiluminescence-immunoassay system
(Diagnostic Products Corporation, Los Angeles, CA). Total
testosterone, dehydroepiandrosterone sulfate (DHEAS), and
17-hydroxyprogesterone were measured following the manu-
facturer’s recommendations (Diagnostic Products Corpora-
tion, Los Angeles, CA). Exclusion of nonclassic congenital
adrenal hyperplasia was based on a basal morning 17-hydrox-
yprogesterone level less than 200 ng/dL.
Statistical Analysis
The normality of distribution of all variables was checked by
using the Kolmogorov–Smirnov test. The results were ex-
pressed as mean  standard deviation (SD) unless otherwise
indicated. The significance of differences between groups
was determined using the unpaired t-test and analysis of var-
iance (ANOVA), as appropriate. Between-group differences
were assessed by chi-square testing. For all analyses, two-
tailed P<.05 was considered statistically significant. Data
analysis was performed using SPSS version 13.0 for Win-
dows statistical software (SPSS, Inc., Chicago IL).Vol. 89, No. 3, March 2008
TABLE 1
Age-stratified prevalence of the metabolic syndrome (MetS) in Brazilian women with polycystic ovary
syndrome.
Age groups (years) MetS N (%) No MetS N (%) Total N (%)
20–24 4 (12.1) 29 (87.9) 33 (100.0)
25–29 13 (31.7) 28 (68.3) 41 (100.0)
30–34 12 (42.9) 16 (57.1) 28 (100.0)
Total 29 (28.4) 73 (71.6) 102 (100.0)
Note: Prevalence of MetS was different across age groups (chi-square test; P¼ .02).
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Clinical Characteristics of Patients
For the entire cohort, the mean age at baseline evaluation was
26.4  5.3 years and mean BMI was 29.4  6.7 kg/m2. The
overall prevalence of women who were overweight or obese
was 25.5% (26 out of 102) and 43.1% (44 out of 102), respec-
tively. The prevalence rates of oligomenorrhea, hirsutism,
and infertility were 56.9%, 41.2%, and 64.7%, respectively.
Prevalence of the Metabolic Syndrome and Glucose
Intolerance
The prevalence of MetS in this cohort of 102 women with
PCOS was 28.4% (n ¼ 29 patients). A considerable propor-
tion (30.4%) of these women fulfilled two criteria, and
26.5% fulfilled one criteria for MetS. Only 14.7% of them
had no MetS factors. Table 1 shows the age-stratified preva-
lence of MetS, where the increasing prevalence according to
age group can be seen. The prevalence of MetS was also sta-
tistically significantly associated with BMI (Table 2). Over-
weight and obese women had a sixfold and 16-fold
increased risk for MetS, respectively, when compared withFertility and Sterilitythe normal BMI group. High waist circumference and high
blood pressure were also more prevalent in the overweight
and obese groups (P<.0001).
Based on the 2-hour glucose level during OGTT, glucose
tolerance was found to be normal in 80 (78.4%) of the 102
women; 20 (19.6%) had impaired glucose tolerance, and
two (2.0%) had noninsulin-dependent diabetes mellitus at
the time of baseline evaluation. When we analyzed fasting
glucose levels according to the recommendations of the Ex-
pert Committee of the American Diabetes Association (22),
we found that 99 (97.1%) women had normal fasting glucose
(<110 mg/dL), and three (2.9%) had impaired fasting glu-
cose (R110 and <126 mg/dL).
The clinical and metabolic characteristics of subgroups
with and without MetS are presented in Table 3. Compared
with women without MetS, the patients with MetS had higher
BMI, waist circumference, and systolic and diastolic blood
pressure as well as higher levels of total cholesterol, triglycer-
ides, fasting glucose, fasting insulin, creatinine, and gamma-
glutamyltransferase and a lower QUICKI index.TABLE 2
Prevalence of themetabolic syndrome and individual abnormalities in Brazilian womenwith polycystic
ovary syndrome stratified by body mass index group.
Body mass index (kg/m2)
<25 (n[ 32) 25–29 (n[ 26) R30 (n[ 44) P valuea
Metabolic syndrome 01 (3.2%) 05 (19.2%) 23 (52.3%) < .0001
High waist circumference 02 (6.3%) 14 (53.8%) 43 (97.7%) < .0001
Hypertriglyceridemia 06 (19.4%) 08 (30.8%) 18 (40.9%) .14
Low HDL-C 18 (62.1%) 19 (76.0%) 34 (85.0%) .09
High blood pressure — 03 (11.5%) 16 (36.4%) < .0001
High fasting glucose — 01 (3.8%) 02 (4.5%) .48
Impaired glucose tolerance 04 (12.5%) 04 (15.4%) 12 (27.3%) .19
NIDDM — — 2 (4.5%) .19
Note: HDL-C, high-density lipoprotein cholesterol; NIDDM, noninsulin-dependent diabetes mellitus.
a Chi-square test.
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TABLE 3
Comparison of clinical and endocrine characteristics of Brazilian women with polycystic ovary
syndrome women with and without the metabolic syndrome (MetS).
Variables MetS (n[ 29) No MetS (n[ 73)
Weight (kg) 84.3  15.0 67.4  17.1a
Body mass index (kg/m2) 34.2  5.3 27.5  6.2a
Waist circumference 101.2  12.3 86.8  15.6a
Systolic blood pressure (mm Hg) 125.8  13.5 109.7  10.3a
Diastolic blood pressure (mm Hg) 81.0  10.5 68.9  9.1a
Prolactin (ng/mL) 13.2  1.5 15.5  1.8
TSH (mU/mL) 1.67  0.14 1.62  0.21
Serum total testosterone (ng/dL) 114.4  35.0 105.6  11.8
DHEAS (ng/dL) 73.3  23.0 97.4  16.5
Total cholesterol (mg/dL) 200.6  39.6 182.5  41.7a
HDL-C (mg/dL) 37.6  8.0 42.3  11.9
LDL-C (mg/dL) 123.7  39.5 119.2  40.5
Triglycerides (mg/dL) 196.2  71.4 103.3  50.6a
Fasting glucose (mg/dL) 88.3  14.1 82.2  10.7a
Fasting insulin (mU/mL) 15.8  9.2 10.2  6.5a
QUICKI 0.33  0.02 0.35  0.04a
Aspartate aminotransferase (mg/dL) 27.5  9.4 26.0  9.8
Alanine aminotransferase (mg/dL) 28.0  12.4 24.6  17.7
Gamma-glutamyltransferase (mg/dL) 29.2  20.9 20.3  8.1a
Urea (mg/dL) 22.2  5.2 22.1  6.0
Creatinine (mg/dL) 1.01  0.16 0.89  0.14a
Note: Data presented as mean  standard deviation. DHEAS, dehydroepiandrosterone sulfate; HDL-C, high-density lipo-
protein cholesterol; LDL-C, low-density lipoprotein cholesterol; QUICKI, quantitative insulin-sensitivity check index;
TSH, thyroid-stimulating hormone.
a Student’s-t test, P< .001.
Soares. Metabolic syndrome in Brazilian PCOS. Fertil Steril 2008.The Metabolic Syndrome Abnormalities
The most prevalent isolated MetS abnormality in women
with PCOS was high-density lipoprotein cholesterol levels
below 50 mg/dL, present in 69.6% (71 out of 102). Other ab-
normalities were increased waist circumference in 57.9%
(59/102), increased serum triglycerides in 31.4% (32 out of
102), hypertension in 18.6% (19 out of 102), and high fasting
glucose concentrations in 2.9% (3 out of 102). Analysis of the
prevalence of other PCOS clinical features according to the
presence of MetS showed a statistically significant associa-
tion with the presence of acanthosis nigricans; the condition
was more frequent in women with MetS than in women
without MetS (Table 4).
DISCUSSION
In this study, the prevalence of MetS in Brazilian women
with PCOS was 28.4%. There are no published references
about age-adjusted prevalence of MetS by sex in the general
Brazilian population (24). Limited information can be ob-
tained from a recent study involving a specific sample of
a rural population from Bahia, Brazil, which showed
a 7% prevalence of MetS for the 25- to 34-year age group,652 Soares et al. Metabolic syndrome in Brazilian PCOSwith higher frequency in women than in men (25). This lim-
itation led us to compare our results with those reported by
Ford et al. for the general U.S. population (26). Despite the
higher prevalence of obesity in the U.S. population, we
found a statistically significant higher prevalence of MetS
in our sample of Brazilian women with PCOS than that
of U.S. women aged 25 to 34 years.
Several studies have been conducted to evaluate the prev-
alence of MetS in women with PCOS. Glueck et al. (10) and
Apridonidze et al. (11) observed that the prevalence of MetS
in U.S. women with PCOS was 46% and 43%, respectively,
much higher than that observed in our study. Conversely,
Vrbıkova et al. (13) did not find a higher prevalence of
MetS in Czech women with PCOS, even though thosewomen
had higher BMI and waist circumference, higher systolic and
diastolic blood pressure, and lower HDL-cholesterol levels
than women without PCOS. In Italian women, Carmina
et al. (14) observed that MetS was more frequent in women
with PCOS than in the general population; however, this
prevalence was much lower than in the United States. These
differences could be attributed to genetic factors or lifestyle
characteristics and dietary habits, such as the higher inci-
dence of obesity in the U.S. population.Vol. 89, No. 3, March 2008
TABLE 4
Prevalence of clinical characteristics in Brazilian women with polycystic ovary syndrome with and
without the metabolic syndrome (MetS).
Prevalence [N (%)]
Variables MetS (N[ 29) No MetS (N[ 73) P valuea
Amenorrhea 21 (72.4) 58 (79.5) .44
Infertility 18 (62.1) 48 (65.8) .72
Hirsutism 14 (48.3) 29 (39.7) .62
Acanthosis 21 (72.4) 29 (39.7) .005
Polycystic ovary morphology 21 (72.4) 56 (76.7) .89
FH cardiovascular disease 12 (41.4) 34 (46.6) .44
FH systemic
arterial hypertension
24 (82.8) 50 (68.5) .34
FH obesity 15 (51.7) 31 (42.5) .62
FH NIDDM 21 (72.4) 46 (63.0) .51
FH dyslipidemia 13 (44.8) 24 (32.9) .28
Note: FH, family history; NIDDM, noninsulin-dependent diabetes mellitus.
a Chi-square test.
Soares. Metabolic syndrome in Brazilian PCOS. Fertil Steril 2008.The occurrence of low HDL-C was the most frequent indi-
vidual MetS component in Brazilian women with PCOS, fol-
lowed by increased waist circumference and increased serum
triglycerides. Other studies have reported similar results and
point to the fact that dyslipidemia is the most common met-
abolic abnormality in PCOS, with a prevalence of up to 70%
according to NCEP criteria (6, 11, 27). Furthermore, it is im-
portant to observe that the majority of our patients (85.3%)
had at least one MetS abnormality, a finding similar to that
found by Apridonidze et al. (11).
A very consistent finding is that the prevalence of MetS is
highly age and BMI dependent (28, 29). In our study, the
prevalence of MetS in women with PCOS aged 20 to 24
years was 12.1%, with a progressive increase to 31.7% in
the 25- to 29-year group and 42.9% in the 30- to 34-year
group. A previous case-control study involving 86 women
with PCOS aged between 18 and 22 years found a MetS
prevalence of 11%, supporting the idea that the prevalence
of MetS in women with PCOS is high in all age groups
(30).
Many women with PCOS (between 38% and 88%) are
overweight or obese, and there is no doubt that adiposity
plays a crucial role in the development and maintenance of
PCOS and strongly influences the severity of both its clinical
and endocrine features in many women (31). Obesity seems
to contribute as an independent factor for MetS abnormalities
(32, 33), and our results are in accordance with this idea,
given that increased waist circumference and hypertension
showed an increasing prevalence with BMI. Nevertheless,
the rates of dyslipidemia and impaired glucose tolerance
showed no statistically significant difference among the
BMI groups, an important finding corroborating the rele-Fertility and Sterilityvance of screening for MetS and other cardiovascular risk
factors in all women with PCOS, regardless of obesity.
Insulin resistance is associated with MetS, and is consid-
ered a common denominator of metabolic alterations that
characterize the syndrome (34, 35). Our data support this hy-
pothesis, with the finding of a statistically significant lower
QUICKI index in women with PCOS and MetS when com-
pared with those without MetS. Corroborating this finding,
we also observed that acanthosis nigricans was more preva-
lent in women with PCOS and MetS.
Recently, several clinical, epidemiological, and biochem-
ical studies have supported the concept that insulin resis-
tance is accompanied by many other alterations that are
not included in the diagnostic criteria for MetS. These con-
ditions include nonalcoholic fatty liver disease and/or nonal-
coholic steatohepatitis, obstructive sleep apnea, and
increased levels of prothrombotic factors, homocysteine,
and proinflammatory cytokines (8). Results of our observa-
tions in women with PCOS show higher gamma-glutamyl-
transferase serum levels in women with MetS than in
women without MetS, which is in accordance with published
data on the subject. Whitfield et al. (36) showed that changes
in enzyme gamma-glutamyltransferase and alanine-amino-
transferase are associated with cardiovascular risk factors.
In the Brazilian population, Araujo et al. (37) found that
gamma-glutamyltransferase activity was associated with
the number of MetS abnormalities in obese women. Addi-
tionally, Setji et al. (38) observed that abnormal aminotrans-
ferase activity is common in women with PCOS (about
15%), and is significantly associated to dyslipidemia and
hyperinsulinemia. Taken together, these data suggest that
women with PCOS may have an increased risk of developing653
many of the consequences of MetS, including nonalcoholic
steatohepatitis.
Despite these relevant findings, it is important to point out
the limitations of our study. We included only cross-sectional
measures; prospective data from this cohort study will be
available in the future to determine conclusively the associa-
tion between PCOS and cardiovascular disease in Brazilian
women. Other limitations include the relatively small sample
size and the fact that only one diagnostic criteria for MetS
were considered. Additionally, the results may be influenced
by the way in which PCOS and MetS were diagnosed.
The findings of this study confirm that the prevalence of
MetS and its individual components, particularly a decreased
high-density lipoprotein cholesterol level, is substantially
higher in women with PCOS than in the general population.
However, the prevalence of MetS in Brazilian women with
PCOS appears to be much lower than that found in the U.S.
population, as previously reported in other non-U.S. studies.
Thus, these women are at increased risk of diabetes mellitus
and cardiovascular disease; it is therefore important to
screen all women with PCOS for cardiovascular risk fac-
tors. Identification and clinical management of this high-
risk group is an important aspect of coronary heart disease
prevention, and better understanding of these issues is crit-
ical to preventing mortality from cardiovascular disease in
these patients.
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